Research Status LANDED

AHD-RESEARCH-001 — Research Status (UPDATED 24/04/2026)

Avina Home Detox LLC Status: ALL 5 SEATS LANDED — synthesis complete Started / Completed: 24/04/2026


Status: COMPLETE

All 5 NEXUS swarm seats have returned. Total research time: ~5-9 minutes per seat in parallel. Token cost: ~$3-5 USD across all seats vs ~$50-200 if attempted inline on Opus.

Seat Topic Status Key Finding
01 NAD IV clinical evidence LANDED No RCTs in AUD/OUD; pilot data only; specific defensible vs avoid claims defined
02 Concierge IV competitive landscape LANDED White space confirmed; AHD position is unoccupied; pricing benchmarks verified
03 In-home IV regulatory map CA/NY/FL LANDED 5 critical landmines identified including AB5, HHA licensure, controlled substance chain of custody
04 Combined detox + IV protocol design LANDED 8-protocol IV library v1.0 with evidence grades; replaces v0.1 placeholder
05 UHNW concierge wellness brand teardown LANDED 3 brand directions for AHD; Swiss transparency vs opacity model analysis; voice cues

Where to Read

The synthesis: AHD-RESEARCH-SYNTHESIS-v1.0.md — the boardroom-ready synthesis of all 5 returns with action items per finding.

Critical headlines from the synthesis:

  1. CA AB5 likely makes the 1099 nurse model illegal. Cost basis shifts.
  2. HHA licensure required in all 3 states. Adds $30K + 60-120 days per state.
  3. NAD has no RCT evidence. Marketing claims must be carefully scoped.
  4. White space is confirmed. No US competitor sits at AHD’s exact intersection.
  5. CA-only Y1 launch is the correct strategy given the regulatory stack.

Documents that need v0.2 update based on the findings

These updates are queued. The synthesis document captures all the changes in one place; individual document updates can be sequenced based on what Fabian wants to walk first.


Status: ALL LANDED · Synthesis complete · Awaiting Fabian’s decision on the 5 forced decisions in the synthesis (nurse classification, capital revision, brand direction, NAD claims discipline, multi-state strategy).